Cerus Q3 2026 total revenue rises 6% to $64.0 million; quarterly net loss widens
Cerus reported third-quarter 2026 total revenue of $64.0 million, up 6% from a year earlier, with product revenue up 10% to $57.7 million. The net loss attributable to Cerus widened to $0.6 million from $0.02 million a year earlier, while the company reiterated its full-year 2026 product revenue guidance of $229 million to $231 million. The release also announced positive topline Phase 3 RedeS results for the INTERCEPT Blood System for red blood cells.
Key points
- Total revenue was $64.0 million versus $60.2 million; product revenue was $57.7 million, up 10%.
- Net loss attributable to Cerus was $0.6 million, or $0.00 per share, versus $0.02 million in the prior-year quarter.
- Full-year 2026 product revenue guidance of $229 million to $231 million was reiterated, including IFC revenue of $23 million to $25 million.
- Cash, cash equivalents and short-term investments were $57.1 million at September 30, 2026.
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.